Oisin Biotechnologies is a company dedicated to developing genetic medicines that address a range of age-related diseases. Their lead candidate aims to build muscle without exercise, which could be used as a therapy to make older people stronger. The company also has assets that selectively kill adipocytes and senescent cells, which are believed to play a significant role in the aging process and the onset of age-related diseases. Oisin has generated impressive data and has already licensed its technology to pharmaceutical companies.